Novo Nordisk is deepening its push for orally available biologics with a multitarget partnership with Orbis Medicines to develop oral alternatives to injectable cardiometabolic treatments. Under the agreement, Orbis could receive undisclosed upfront payments plus total development and commercial milestone payments of up to $1.4 billion, along with tiered royalties on future product sales. Orbis’ nGen platform (nCycles) is designed to tackle oral bioavailability for macrocyclic molecules that typically struggle with permeability and stability. Novo is also making a strategic investment in Orbis, tying the collaboration to Orbis’ ongoing macrocycle discovery pipeline. The partnership follows earlier Orbis funding momentum, including a NEA-led Series A in 2025 that raised $103.3 million, and aligns with Novo’s broader R&D reorientation toward AI-augmented discovery workflows and patient-friendly dosing forms. Regulators have already begun to validate macrocycle approaches in the class, and the Novo-Orbis deal extends that validation to next-generation oral cardiometabolic candidates targeting obesity, diabetes, and heart disease.